Comparative Pharmacology
Head-to-head clinical analysis: MEDIHALER ERGOTAMINE versus WIGRETTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEDIHALER ERGOTAMINE versus WIGRETTES.
MEDIHALER ERGOTAMINE vs WIGRETTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ergotamine is a serotonin (5-HT1B/1D) receptor agonist with additional affinity for 5-HT2, dopamine D2, and alpha-adrenergic receptors. It causes vasoconstriction of cranial blood vessels and inhibits neurogenic inflammation.
Nicotine replacement therapy: binds to nicotinic acetylcholine receptors in the brain, releasing dopamine and providing nicotine to reduce withdrawal symptoms and cravings.
One inhalation (0.36 mg ergotamine) at onset of migraine; may repeat after 5 minutes if needed, up to 6 inhalations per attack and 15 per week.
1 mg sublingually as needed for smoking cessation, up to 4 times daily. Maximum daily dose: 4 mg.
None Documented
None Documented
The terminal elimination half-life is approximately 2 hours for the initial phase, followed by a prolonged terminal phase of 21-30 hours due to slow release from tissue binding sites. This long terminal half-life contributes to the risk of accumulation and toxicity with frequent dosing.
Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to 24-30 hours in moderate renal impairment.
Ergotamine is extensively metabolized in the liver. Approximately 90% of the dose is excreted as metabolites in the bile/feces, with less than 3% excreted unchanged in urine.
Renal excretion of unchanged drug accounts for 50-60% of the dose; biliary/fecal elimination accounts for 20-30%; remainder metabolized.
Category D/X
Category C
Ergot Alkaloid
Ergot Alkaloid